z-logo
Premium
P2–006: A glucocorticoid–amyloid precursor protein connection
Author(s) -
Catania Caterina,
Sotiropoulos Ioannis,
Silva Rui,
Sousa Nuno,
Almeida Osborne F.X.
Publication year - 2006
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2006.05.843
Subject(s) - glucocorticoid , amyloid precursor protein , hippocampal formation , neuroprotection , endocrinology , medicine , hippocampus , neurotoxicity , dexamethasone , synaptic plasticity , neuroscience , biology , chemistry , alzheimer's disease , toxicity , receptor , disease
ferences in the cellular inflammatory response (reactive astrocytes & microglia), in beta amyloid 1-42 deposition, and in the presence of C. pneumoniae in the brain. Results: Initial results indicate that, with antibiotic treatment, astrocytic activation was more prominent at 3 months post-infection as compared to 6 months post-infection. Animals infected and treated at 7-21 days post-infection, demonstrated numerous reactive astrocytes at 3 months as compared to 6 months, which showed reduced numbers of reactive astrocytes. Intriguingly, in animals treated at 7-21 days post-infection, immunolabeling for C. pneumoniae in the brains was comparable between 3 months and 6 months, although the number of amyloid plaques on average was greater in the 3 month animals. With treatment delayed until 56-70 days post-infection, less cellular reactivity was recognized in both the 3 and 6 month animals, although labeling for C. pneumoniae and amyloid was still prominent, especially in the 6 month animals. Conclusion: These data suggest that early antibiotic treatment, 7-21 days post-infection, may help to modulate the cellular inflammatory processes following C. pneumoniae infection, which ultimately may affect the extent of infection and subsequent amyloid deposition in the mouse brain.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here